Literature DB >> 29264432

What drives the wheel towards long-term outcome in advanced GIST, its size, genotype or may be a pill or two of imatinib?

Vikas Ostwal1, Anant Ramaswamy1.   

Abstract

Entities:  

Year:  2017        PMID： 29264432      PMCID： PMC5723726          DOI： 10.21037/tgh.2017.11.08

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  17 in total

1.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Authors:  H Joensuu; P J Roberts; M Sarlomo-Rikala; L C Andersson; P Tervahartiala; D Tuveson; S Silberman; R Capdeville; S Dimitrijevic; B Druker; G D Demetri
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

2.  Imatinib Mesylate for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors Expressing KIT: A Decade Experience from Taiwan.

Authors:  Chun-Nan Yeh; Yen-Yang Chen; Jeng-Hwei Tseng; Jen-Shi Chen; Tsung-Wen Chen; Chun-Yi Tsai; Chi-Tung Cheng; Yi-Yin Jan; Miin-Fu Chen
Journal:  Transl Oncol       Date:  2011-12-01       Impact factor: 4.243

3.  Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST.

Authors:  Agnieszka Wozniak; Piotr Rutkowski; Patrick Schöffski; Isabelle Ray-Coquard; Isabelle Hostein; Hans-Ulrich Schildhaus; Axel Le Cesne; Elzbieta Bylina; Janusz Limon; Jean-Yves Blay; Janusz A Siedlecki; Eva Wardelmann; Raf Sciot; Jean-Michel Coindre; Maria Debiec-Rychter
Journal:  Clin Cancer Res       Date:  2014-10-07       Impact factor: 12.531

4.  Early outcomes of exon 11 mutants in GIST treated with standard dose Imatinib.

Authors:  Anant Ramaswamy; Munita Bal; Rohit Swami; Omshree Shetty; Subhadeep Bose; Trupti Pai; Mamta Gurav; Sudeep Gupta; Vikas Ostwal
Journal:  Ann Transl Med       Date:  2017-03

5.  Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience.

Authors:  A Wozniak; P Rutkowski; A Piskorz; M Ciwoniuk; C Osuch; E Bylina; J Sygut; M Chosia; J Rys; K Urbanczyk; W Kruszewski; P Sowa; J Siedlecki; M Debiec-Rychter; J Limon
Journal:  Ann Oncol       Date:  2011-04-28       Impact factor: 32.976

6.  Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

Authors:  Michael C Heinrich; Robert G Maki; Christopher L Corless; Cristina R Antonescu; Amy Harlow; Diana Griffith; Ajia Town; Arin McKinley; Wen-Bin Ou; Jonathan A Fletcher; Christopher D M Fletcher; Xin Huang; Darrel P Cohen; Charles M Baum; George D Demetri
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

7.  Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.

Authors:  Piotr Rutkowski; Alessandro Gronchi; Peter Hohenberger; Sylvie Bonvalot; Patrick Schöffski; Sebastian Bauer; Elena Fumagalli; Pawel Nyckowski; Buu-Phuc Nguyen; Jan Martijn Kerst; Marco Fiore; Elzbieta Bylina; Mathias Hoiczyk; Annemieke Cats; Paolo G Casali; Axel Le Cesne; Jürgen Treckmann; Eberhard Stoeckle; Johannes H W de Wilt; Stefan Sleijfer; Ronald Tielen; Winette van der Graaf; Cornelis Verhoef; Frits van Coevorden
Journal:  Ann Surg Oncol       Date:  2013-06-13       Impact factor: 5.344

8.  Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  George D Demetri; Peter Reichardt; Yoon-Koo Kang; Jean-Yves Blay; Piotr Rutkowski; Hans Gelderblom; Peter Hohenberger; Michael Leahy; Margaret von Mehren; Heikki Joensuu; Giuseppe Badalamenti; Martin Blackstein; Axel Le Cesne; Patrick Schöffski; Robert G Maki; Sebastian Bauer; Binh Bui Nguyen; Jianming Xu; Toshirou Nishida; John Chung; Christian Kappeler; Iris Kuss; Dirk Laurent; Paolo G Casali
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

9.  Neoadjuvant Imatinib in Locally Advanced Gastrointestinal stromal Tumours, Will Kit Mutation Analysis Be a Pathfinder?

Authors:  Anant Ramaswamy; Vikas Ostwal; Omshree Shetty; Arvind Sahu; Davinder Paul; Trupti Pai; Mamta Gurav; Nitin Shetty; Shailesh Shrikhande
Journal:  J Gastrointest Cancer       Date:  2016-12

10.  Liquid biopsy in gastrointestinal stromal tumors: a novel approach.

Authors:  Margherita Nannini; Annalisa Astolfi; Milena Urbini; Guido Biasco; Maria A Pantaleo
Journal:  J Transl Med       Date:  2014-08-14       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.